PhaseBio Pharmaceuticals Statistics
Total Valuation
PHASQ has a market cap or net worth of $49. The enterprise value is -$2.43 million.
Market Cap | 49 |
Enterprise Value | -2.43M |
Important Dates
The last earnings date was Wednesday, March 22, 2023.
Earnings Date | Mar 22, 2023 |
Ex-Dividend Date | n/a |
Share Statistics
Shares Outstanding | n/a |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 0.18% |
Owned by Institutions (%) | 4.09% |
Float | 46.21M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.00 |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.47
Current Ratio | 0.47 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | 0.19 |
Debt / FCF | n/a |
Interest Coverage | -90.76 |
Financial Efficiency
Return on equity (ROE) is -23.71% and return on invested capital (ROIC) is -30.61%.
Return on Equity (ROE) | -23.71% |
Return on Assets (ROA) | 125.58% |
Return on Capital (ROIC) | -30.61% |
Revenue Per Employee | $13,633 |
Profits Per Employee | $463,932 |
Employee Count | 60 |
Asset Turnover | 0.02 |
Inventory Turnover | n/a |
Taxes
Income Tax | -4.46M |
Effective Tax Rate | -19.08% |
Stock Price Statistics
The stock price has decreased by -99.86% in the last 52 weeks. The beta is 2.08, so PHASQ's price volatility has been higher than the market average.
Beta (1Y) | 2.08 |
52-Week Price Change | -99.86% |
50-Day Moving Average | n/a |
200-Day Moving Average | 0.00 |
Relative Strength Index (RSI) | 38.64 |
Average Volume (30 Days) | 54 |
Short Selling Information
Short Interest | 2.07M |
Short Previous Month | 1.47M |
Short % of Shares Out | n/a |
Short % of Float | 4.47% |
Short Ratio (days to cover) | 1.89 |
Income Statement
In the last 12 months, PHASQ had revenue of $818,000 and earned $27.84 million in profits. Earnings per share was $0.59.
Revenue | 818,000 |
Gross Profit | 818,000 |
Operating Income | 29.35M |
Pretax Income | 26.50M |
Net Income | 27.84M |
EBITDA | 28.17M |
EBIT | 26.23M |
Earnings Per Share (EPS) | $0.59 |
Balance Sheet
The company has $7.80 million in cash and $5.37 million in debt, giving a net cash position of $2.43 million.
Cash & Cash Equivalents | 7.80M |
Total Debt | 5.37M |
Net Cash | 2.43M |
Net Cash Per Share | n/a |
Equity / Book Value | -117.40M |
Book Value Per Share | n/a |
Working Capital | -13.12M |
Cash Flow
In the last 12 months, operating cash flow was -$59.42 million and capital expenditures -$2.40 million, giving a free cash flow of -$61.82 million.
Operating Cash Flow | -59.42M |
Capital Expenditures | -2.40M |
Free Cash Flow | -61.82M |
FCF Per Share | -$1.26 |
Margins
Gross margin is 100.00%, with operating and profit margins of 3,588.21% and 3,402.93%.
Gross Margin | 100.00% |
Operating Margin | 3,588.21% |
Pretax Margin | 3,239.80% |
Profit Margin | 3,402.93% |
EBITDA Margin | 3,443.23% |
EBIT Margin | 3,206.06% |
FCF Margin | -7,557.70% |
Dividends & Yields
PHASQ does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.49% |
Shareholder Yield | -2.49% |
Earnings Yield | 56,808,018.37% |
FCF Yield | -126,167,346.94% |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
PHASQ has an Altman Z-Score of -23.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -23.27 |
Piotroski F-Score | 3 |